{"id":45028,"date":"2025-01-24T12:58:16","date_gmt":"2025-01-24T12:58:16","guid":{"rendered":"https:\/\/www.theisn.org\/?page_id=45028"},"modified":"2026-06-01T08:29:43","modified_gmt":"2026-06-01T08:29:43","slug":"sglt2i-toolkit","status":"publish","type":"page","link":"https:\/\/www.theisn.org\/initiatives\/toolkits\/sglt2i-toolkit\/","title":{"rendered":"Optimization of SGLT2i Therapy Toolkit"},"content":{"rendered":"<p>[vc_row][vc_column][vc_empty_space height=&#8221;14px&#8221;][vc_column_text]<\/p>\n<p style=\"text-align: center\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-30644\" src=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/04\/ASPC_CardioRenal_Logo-300x85.png\" alt=\"\" width=\"233\" height=\"66\" \/>\u00a0 \u00a0<img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-30643\" src=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/04\/ISN_CardioRenal_Logo-300x189.png\" alt=\"\" width=\"185\" height=\"117\" \/>\u00a0 \u00a0\u00a0<img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-30642\" src=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/04\/KDIGO_CardioRenal_Logo-1.png\" alt=\"\" width=\"89\" height=\"80\" \/>\u00a0 \u00a0 \u00a0<img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-30638\" src=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/04\/RPA_CardioRenal_Logo-300x128.png\" alt=\"\" width=\"170\" height=\"73\" \/><\/p>\n<p>[\/vc_column_text][vc_column_text]The toolkit on the\u00a0optimization of SGLT2i therapy is the next output of a multi-society cardio-kidney-metabolic initiative, led by the ISN, to co-create toolkits for advancing the prevention and management of cardio-kidney complications.<\/p>\n<p>The toolkit consists of\u00a0focused and practical infographics, serving as hands-on references for nephrologists, cardiologists and other healthcare professionals involved in the multidisciplinary care of patients with cardio-kidney-metabolic complications.<\/p>\n<p>Scroll down for educational and clinical infographics on:<\/p>\n<ul>\n<li>Nuts and Bolts of SGLT2i Therapy in the Intersection of Kidney and Cardiovascular Disease<\/li>\n<li>Practical Points for SGLT2 Inhibitor Usage<\/li>\n<li>Mitigate Adverse Effects of SGLT2 Inhibitors<\/li>\n<li>SGLT2 Inhibitor Cold Map<\/li>\n<li>Talking to Your Patients About SGLT2 Inhibitor Therapy<\/li>\n<li>Understanding SGLT2 Inhibitor Therapy<\/li>\n<\/ul>\n<p style=\"font-weight: 400\">Additional resources developed as part of the wider CKM initiative can be found <a href=\"https:\/\/www.theisn.org\/initiatives\/toolkits\/ckm-roadmap\/\" target=\"_blank\" rel=\"noopener\">here<\/a>.<\/p>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row equal_height=&#8221;yes&#8221; content_placement=&#8221;bottom&#8221;][vc_column][vc_tta_accordion spacing=&#8221;5&#8243; gap=&#8221;5&#8243; c_position=&#8221;right&#8221; active_section=&#8221;&#8221; collapsible_all=&#8221;true&#8221; el_class=&#8221;accordion-isn&#8221;][vc_tta_section title=&#8221;Overview: Nuts &amp; Bolts of SGLT2 Inhibitor Therapy&#8221; tab_id=&#8221;Overview&#8221;][vc_row_inner][vc_column_inner width=&#8221;1\/3&#8243; offset=&#8221;vc_col-xs-6&#8243;][vc_single_image image=&#8221;45199&#8243; img_size=&#8221;175&#215;250&#8243; alignment=&#8221;center&#8221; onclick=&#8221;link_image&#8221;][vc_column_text]<\/p>\n<h4 style=\"text-align: center;\">Nuts and Bolts of SGLT2i Therapy<\/h4>\n<h5 style=\"text-align: center;\"><strong>Download here<\/strong>: <a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/01\/CKM_SGLT2i_Nuts-and-Bolts-of-English.pdf\" target=\"_blank\" rel=\"noopener\">English<\/a> |\u00a0 <a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2026\/03\/CKM_SGLT2i_Nuts-and-Bolts_French.pdf\">French<\/a> | <a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/06\/CKM_SGLT2i_Nuts-and-Bolts_German.pdf\" target=\"_blank\" rel=\"noopener\">German<\/a> |\u00a0\u00a0<a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/06\/CKM_SGLT2i_Nuts-and-Bolts_Spanish.pdf\" target=\"_blank\" rel=\"noopener\">Spanish<\/a><\/h5>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/3&#8243; offset=&#8221;vc_col-xs-6&#8243;][vc_empty_space height=&#8221;24px&#8221;][vc_single_image image=&#8221;45197&#8243; img_size=&#8221;large&#8221; alignment=&#8221;center&#8221; style=&#8221;vc_box_rounded&#8221; onclick=&#8221;link_image&#8221; zoom_icon=&#8221;yes&#8221;][vc_empty_space height=&#8221;26px&#8221;][vc_column_text]<\/p>\n<h4 style=\"text-align: center;\">Practical Points for SGLT2i Usage<\/h4>\n<h5 style=\"text-align: center;\"><strong>Download here<\/strong>: <a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/01\/CKM_SGLT2i_Practical-Points_English-1.pdf\" target=\"_blank\" rel=\"noopener\">English<\/a> | <a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2026\/01\/French_CKM_SGLT2i_Practical-Points.pdf\" target=\"_blank\" rel=\"noopener\">French<\/a> | <a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/06\/CKM_SGLT2i_Practical-Points_German.pdf\" target=\"_blank\" rel=\"noopener\">German<\/a> |\u00a0\u00a0<a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/06\/CKM_SGLT2i_Practical-Points_Spanish.pdf\" target=\"_blank\" rel=\"noopener\">Spanish<\/a><\/h5>\n<p>&nbsp;[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/3&#8243; offset=&#8221;vc_col-xs-6&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section title=&#8221;Mitigating Adverse Effects of SGLT2 Inhibitors&#8221; tab_id=&#8221;Mitigating&#8221;][vc_row_inner][vc_column_inner width=&#8221;1\/3&#8243; offset=&#8221;vc_col-xs-6&#8243;][\/vc_column_inner][vc_column_inner width=&#8221;1\/3&#8243; offset=&#8221;vc_col-xs-6&#8243;][vc_single_image image=&#8221;45202&#8243; img_size=&#8221;full&#8221; alignment=&#8221;center&#8221; onclick=&#8221;link_image&#8221; lightbox=&#8221;yes&#8221; zoom_icon=&#8221;yes&#8221;][vc_column_text]<\/p>\n<h5 style=\"text-align: center;\"><strong>Download here: <\/strong><a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/01\/CKM_SGLT2i_Mitigating_English.pdf\" target=\"_blank\" rel=\"noopener\">English<\/a> |\u00a0\u00a0<a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2026\/03\/CKM_SGLT2i_Mitigating_French.pdf\" target=\"_blank\" rel=\"noopener\">French<\/a> |\u00a0\u00a0<a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/06\/CKM_SGLT2i_Mitigating_German.pdf\" target=\"_blank\" rel=\"noopener\">German<\/a> |\u00a0<a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/06\/CKM_SGLT2i_Mitigating_Spanish.pdf\" target=\"_blank\" rel=\"noopener\">Spanish<\/a><\/h5>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/3&#8243; offset=&#8221;vc_col-xs-6&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section title=&#8221;SGLT2 Inhibitor Cold Map&#8221; tab_id=&#8221;ColdMap&#8221;][vc_row_inner][vc_column_inner width=&#8221;1\/3&#8243; offset=&#8221;vc_col-xs-6&#8243;][\/vc_column_inner][vc_column_inner width=&#8221;1\/3&#8243; offset=&#8221;vc_col-xs-6&#8243;][vc_images_carousel images=&#8221;48372,48371,48370&#8243; img_size=&#8221;medium&#8221; speed=&#8221;&#8221; css=&#8221;.vc_custom_1751283246778{padding-left: 38px !important;}&#8221;][vc_column_text]<\/p>\n<h5 style=\"text-align: center;\"><strong>Download here<\/strong>: <a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/06\/CKM_SGLT2i_ColdMap_English.pdf\" target=\"_blank\" rel=\"noopener\">English<\/a> | <a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2026\/01\/CKM_SGLT2i_ColdMap_French.pdf\">French<\/a>\u00a0| <a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/06\/CKM_SGLT2i_ColdMap_German.pdf\" target=\"_blank\" rel=\"noopener\">German<\/a> |\u00a0 <a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/06\/CKM_SGLT2i_ColdMap_Spanish.pdf\" target=\"_blank\" rel=\"noopener\">Spanish<\/a><\/h5>\n<p>&nbsp;[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/3&#8243; offset=&#8221;vc_col-xs-6&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section title=&#8221;Engaging with Patients&#8221; tab_id=&#8221;Patients&#8221;][vc_row_inner][vc_column_inner width=&#8221;1\/3&#8243; offset=&#8221;vc_col-xs-6&#8243;][vc_single_image image=&#8221;45212&#8243; img_size=&#8221;medium&#8221; alignment=&#8221;center&#8221; style=&#8221;vc_box_rounded&#8221; onclick=&#8221;link_image&#8221;][vc_column_text]<\/p>\n<h4 style=\"text-align: center;\">Physician-Facing Tool<\/h4>\n<h5 style=\"text-align: center;\"><strong>Download here<\/strong>: <a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/01\/CKM_SGLT2i_Physician_English.pdf\" target=\"_blank\" rel=\"noopener\">English<\/a> |\u00a0 <a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2026\/03\/CKM_SGLT2i_Physician_French.pdf\">French<\/a> | <a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/06\/CKM_SGLT2i_Physician_German.pdf\" target=\"_blank\" rel=\"noopener\">German<\/a> |\u00a0\u00a0<a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/06\/CKM_SGLT2i_Physician_Spanish.pdf\" target=\"_blank\" rel=\"noopener\">Spanish<\/a><\/h5>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/3&#8243; offset=&#8221;vc_col-xs-6&#8243;][vc_images_carousel images=&#8221;45107,45214&#8243; img_size=&#8221;210&#215;300&#8243; speed=&#8221;&#8221; css=&#8221;.vc_custom_1737990875776{padding-left: 38px !important;}&#8221;][vc_column_text]<\/p>\n<h4 style=\"text-align: center;\">Patient-Facing Tool<\/h4>\n<h5 style=\"text-align: center;\"><strong>Download here<\/strong>: <a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/01\/CKM_SGLT2i_Patient_English.pdf\" target=\"_blank\" rel=\"noopener\">English<\/a> | <a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2026\/03\/CKM_SGLT2i_Patient_French.pdf\">French<\/a> | <a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/06\/CKM_SGLT2i_Patient_German.pdf\" target=\"_blank\" rel=\"noopener\">German<\/a> |\u00a0<a href=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2025\/06\/CKM_SGLT2i_Patient_Spanish.pdf\" target=\"_blank\" rel=\"noopener\">Spanish<\/a><\/h5>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/3&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section title=&#8221;Additional Resources&#8221; tab_id=&#8221;Additional&#8221;][vc_row_inner][vc_column_inner width=&#8221;1\/3&#8243;][vc_single_image image=&#8221;45149&#8243; img_size=&#8221;medium&#8221; alignment=&#8221;center&#8221; onclick=&#8221;custom_link&#8221; img_link_target=&#8221;_blank&#8221; link=&#8221;https:\/\/eur05.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fx.com%2Fi%2Fspaces%2F1OyKAZbZYZLGb&amp;data=05%7C02%7Cmmoorthy%40Theisn.org%7Cc0915aad298542f9815408dce6e8e158%7C9353336200694ec4b905d4dcc7a8a0ef%7C0%7C0%7C638639135092656187%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=RgIgBWVX3sKIeAz4yQul%2B%2Fr51QBr0Tog41ILd%2BfOpwQ%3D&amp;reserved=0&#8243;][vc_column_text]<\/p>\n<h5 style=\"text-align: center\">Listen to a recording of the World Heart Day 2025 ISN X Space on SGLT2 Inhibitors <a href=\"https:\/\/eur05.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fx.com%2Fi%2Fspaces%2F1OyKAZbZYZLGb&amp;data=05%7C02%7Cmmoorthy%40Theisn.org%7Cc0915aad298542f9815408dce6e8e158%7C9353336200694ec4b905d4dcc7a8a0ef%7C0%7C0%7C638639135092656187%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=RgIgBWVX3sKIeAz4yQul%2B%2Fr51QBr0Tog41ILd%2BfOpwQ%3D&amp;reserved=0\" target=\"_blank\" rel=\"noopener\">here<\/a>.<\/h5>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/3&#8243;][\/vc_column_inner][vc_column_inner width=&#8221;1\/3&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section title=&#8221;Acknowledgements&#8221; tab_id=&#8221;Acknowledgements&#8221; el_class=&#8221;acknowledgements&#8221;][vc_toggle title=&#8221;Steering Committee Members&#8221;]<\/p>\n<div class=\"row\">\n<div class=\"col-lg-3 col-md-4 col-sm-6\" style=\"float: left;padding-right: 40px\">\n<p style=\"text-align: center\"><img decoding=\"async\" class=\"alignnone wp-image-30570\" style=\"height: 150px\" src=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/04\/24-April-Insight-Article_Welcome-to-New-ISN-Committee-and-Working-Group-Leaders_SS-DT-002-10.jpg\" alt=\"\" height=\"150px\" \/><br \/>\n<strong>Roberto <\/strong><strong>Pecoits-Filho<\/strong><br \/>\nISN<br \/>\n<em>Nephrologist<\/em><\/p>\n<\/div>\n<div class=\"col-lg-3 col-md-4 col-sm-6\" style=\"float: left;padding-right: 40px\">\n<p style=\"text-align: center\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-30704\" src=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/04\/AngelaWang_RAASi-267x300.jpeg\" alt=\"\" width=\"133\" height=\"150\" \/><br \/>\n<strong>Angela Wang<\/strong><br \/>\nISN<br \/>\n<em>Nephrologist<\/em><\/p>\n<\/div>\n<div class=\"col-lg-3 col-md-4 col-sm-6\" style=\"float: left;padding-right: 40px\">\n<p style=\"text-align: center\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-30701\" src=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/04\/CharlesHerzog_RAASi-235x300.jpeg\" alt=\"\" width=\"118\" height=\"150\" \/><br \/>\n<strong>Charles Herzog<\/strong><br \/>\nKDIGO<br \/>\n<em>Cardiologist<\/em><\/p>\n<\/div>\n<div class=\"col-lg-3 col-md-4 col-sm-6\" style=\"float: left;padding-right: 40px\">\n<p style=\"text-align: center\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-30705\" src=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/04\/DebasishBanerjee_RAASi-239x300.jpeg\" alt=\"\" width=\"119\" height=\"150\" \/><br \/>\n<strong>Debasish Banerjee<\/strong><br \/>\nISN<br \/>\n<em>Nephrologist<\/em><\/p>\n<\/div>\n<div class=\"col-lg-3 col-md-4 col-sm-6\" style=\"float: left;padding-right: 40px\">\n<p style=\"text-align: center\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-30698\" src=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/04\/GiuseppeRosano_RAASi-254x300.jpeg\" alt=\"\" width=\"127\" height=\"150\" \/><br \/>\n<strong>Giuseppe Rosano<\/strong><br \/>\nHFA<br \/>\n<em>Cardiologist<\/em><\/p>\n<\/div>\n<div class=\"col-lg-3 col-md-4 col-sm-6\" style=\"float: left;padding-right: 40px\">\n<p style=\"text-align: center\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-30697\" src=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/04\/MarthaGulati_RAASi-231x300.png\" alt=\"\" width=\"116\" height=\"150\" \/><br \/>\n<strong>Martha Gulati<\/strong><br \/>\nASPC<br \/>\n<em>Cardiologist<\/em><\/p>\n<\/div>\n<div class=\"col-lg-3 col-md-4 col-sm-6\" style=\"float: left;padding-right: 40px\">\n<p style=\"text-align: center\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-30695\" src=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/04\/EdgarLerma_RAASi.png\" alt=\"\" width=\"121\" height=\"150\" \/><br \/>\n<strong>Edgar Lerma<\/strong><br \/>\nRPA<br \/>\n<em>Nephrologist<\/em><\/p>\n<\/div>\n<\/div>\n<p>[\/vc_toggle][vc_toggle title=&#8221;Young Professionals&#8221;]<\/p>\n<ul>\n<li><strong>Amina Rakisheva<\/strong> &#8211; <em>Cardiologist<\/em><\/li>\n<li><strong>Fadi Jouhra<\/strong> &#8211;\u00a0<em>Cardiologist<\/em><\/li>\n<li><strong>Henry Wu<\/strong> &#8211; <em>Nephrologist<\/em><\/li>\n<li><strong>Michelle Carlson<\/strong> &#8211;\u00a0<em>Cardiologist<\/em><\/li>\n<li><strong>Michelle Wong<\/strong> &#8211; <em>Nephrologist<\/em><\/li>\n<li><strong>Nedda<\/strong> <strong>Dastmalchi<\/strong> &#8211; <em>Cardiologist<\/em><\/li>\n<li><strong>Suman Behera<\/strong> &#8211;\u00a0<em>Nephrologist<\/em><\/li>\n<li><strong>Viviane Calice-Silva<\/strong> &#8211;\u00a0<em>Nephrologist<\/em><\/li>\n<\/ul>\n<p>[\/vc_toggle][vc_empty_space height=&#8221;14px&#8221;][vc_column_text]<\/p>\n<h5 class=\"vc_empty_space\">Thank you to our reviewers and translators: Rolando Claure<\/h5>\n<h5>Thank you also to the <a href=\"https:\/\/www.theisn.org\/in-action\/advocacy\/advocacy-activities\/patient-liaison-advisory-group\/\" target=\"_blank\" rel=\"noopener noreferrer\">ISN Patient Liaison Advisory Group<\/a>\u00a0for their input into the patient tool.<\/h5>\n<p>[\/vc_column_text][\/vc_tta_section][vc_tta_section title=&#8221;References&#8221; tab_id=&#8221;References&#8221;][vc_column_text]<\/p>\n<ol>\n<li>2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.<\/li>\n<li>American Diabetes Association.\u00a0(2023). Chronic kidney disease and risk management: Standards of medical care in diabetes\u20142023.\u00a0<em>Diabetes Care<\/em>, 46(Supplement_1), S191-S202. DOI: 10.2337\/dc23-S015<\/li>\n<li>American Diabetes Association.\u00a0<em>Standards of Medical Care in Diabetes-2022<\/em>\u00a0Abridged for Primary Care Providers. Clin Diabetes. 2022 Jan;40(1):10-38. doi: 10.2337\/cd22-as01. PMID: 35221470; PMCID: PMC8865785.<\/li>\n<li>Garc\u00eda Carro, C., Bedia Raba, A., Banegas Deras, E. J., Vigara, L. A., Valero San Cecilio, R., Cruzado Vega, L., Gavela, E., Gonz\u00e1lez, G. M. E., P\u00e9rez-Flores, I., &amp; Sanchez-Bielsa, F. (2022). FC 116: SGLT2 inhibitors in kidney transplantation: A multicenter study.\u00a0<em>Nephrology Dialysis Transplantation, 37<\/em>(Suppl_3). https:\/\/doi.org\/10.1093\/ndt\/gfac124.001<\/li>\n<li>Heerspink, H. J. L., Stef\u00e1nsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F. F., &#8230; &amp; Wheeler, D. C.\u00a0(2020). Dapagliflozin in patients with chronic kidney disease.\u00a0<em>The New England Journal of Medicine<\/em>, 383(15), 1436-1446. DOI: 10.1056\/NEJMoa2024816<\/li>\n<li>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr;105(4S):S117-S314. doi: 10.1016\/j.kint.2023.10.018. PMID: 38490803.<\/li>\n<li>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.\u00a0<em>Kidney Int.\u00a0<\/em>2022;102(5S):S1-S127. doi: 10.1016\/j.kint.2022.06.008.<\/li>\n<li>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016\/j.kint.2021.05.021. PMID: 34556256.<\/li>\n<li>Krishnan A, Shankar M, Lerma EV, Wiegley N; GlomCon Editorial Team. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator? Kidney Med. 2023 Feb 1;5(4):100608. doi: 10.1016\/j.xkme.2023.100608. PMID: 36915368; PMCID: PMC10006698.<\/li>\n<li>McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK; ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct 1;44(37):3627-3639. doi: 10.1093\/eurheartj\/ehad195. Erratum in: Eur Heart J. 2024 Jan 1;45(1):53. doi: 10.1093\/eurheartj\/ehad613. PMID: 37622666.<\/li>\n<li>McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z., Dagogo-Jack, S., &#8230; &amp; Mahaffey, K. W.\u00a0(2021). Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis.\u00a0<em>JAMA Cardiology<\/em>, 6(2), 148-158. DOI: 10.1001\/jamacardio.2020.4511<\/li>\n<li>McQuarrie EP, Gillis KA, Mark PB. Seven suggestions for successful SGLT2i use in glomerular disease &#8211; a standalone CKD therapy? Curr Opin Nephrol Hypertens. 2022 May 1;31(3):272-277. doi: 10.1097\/MNH.0000000000000786. Epub 2022 Feb 25. PMID: 35220316.<\/li>\n<li>Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Raalte, D. H., &amp; van Bommel, E. J.\u00a0(2018). Kidney effects of SGLT2 inhibitors and GLP-1 receptor agonists: From physiology to clinical outcomes.\u00a0<em>Clinical Journal of the American Society of Nephrology<\/em>, 13(4), 798-810. DOI: 10.2215\/CJN.08820817<\/li>\n<li>Neuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., &#8230; &amp; Jardine, M. J.\u00a0(2019). SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis.\u00a0<em>The Lancet Diabetes &amp; Endocrinology<\/em>, 7(11), 845-854. DOI: 10.1016\/S2213-8587(19)30256-6<\/li>\n<li>Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists&#8217; Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022 Nov 19;400(10365):1788-1801. doi: 10.1016\/S0140-6736(22)02074-8. Epub 2022 Nov 6. PMID: 36351458; PMCID: PMC7613836<\/li>\n<li>Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Chalmers, J., &#8230; &amp; Mahaffey, K. W.\u00a0(2019). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.\u00a0<em>The New England Journal of Medicine<\/em>, 380(24), 2295-2306. DOI: 10.1056\/NEJMoa1811744<\/li>\n<li>SGLT2 inhibitors across the spectrum of chronic kidney disease.\u00a0(2024).\u00a0<em>Postgraduate Medicine<\/em>, 136(5), 481-493. DOI: 10.1080\/00325481.2024.2418795<\/li>\n<li>The EMPA-KIDNEY Collaborative Group.\u00a0(2023). Empagliflozin in patients with chronic kidney disease.\u00a0<em>The New England Journal of Medicine<\/em>, 388(2), 117-127. DOI: 10.1056\/NEJMoa2204233<\/li>\n<li>Wheeler DC, Toto RD, Stef\u00e1nsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Pecoits-Filho R, Correa-Rotter R, Rossing P, Sj\u00f6str\u00f6m CD, Umanath K, Langkilde AM, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney eventsin patients with IgA nephropathy. Kidney Int. 2021 Jul;100(1):215-224. doi: 10.1016\/j.kint.2021.03.033. Epub 2021 Apr 18. PMID: 33878338.<\/li>\n<li>Writing Committee Members; ACC\/AHA Joint Committee Members. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure. J Card Fail. 2022 May;28(5):e1-e167. doi: 10.1016\/j.cardfail.2022.02.010. Epub 2022 Apr 1. PMID: 35378257.<\/li>\n<li>Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney Int Rep. 2022 May 5;7(7):1463-1476. doi: 10.1016\/j.ekir.2022.04.094. PMID: 35812300; PMCID: PMC9263228.<\/li>\n<li>Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., &#8230; &amp; Johansen, O. E.\u00a0(2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.\u00a0<em>The New England Journal of Medicine<\/em>, 373(22), 2117-2128. DOI: 10.1056\/NEJMoa1504720<\/li>\n<\/ol>\n<p>[\/vc_column_text][\/vc_tta_section][vc_tta_section title=&#8221;Support&#8221; tab_id=&#8221;Support&#8221;][vc_column_text]<\/p>\n<h6 style=\"text-align: center\">The Optimization of SGLT2i Therapy Toolkit has been developed with support from unrestricted educational grants from AstraZeneca and Boehringer Ingelheim<\/h6>\n<p>[\/vc_column_text][\/vc_tta_section][vc_tta_section title=&#8221;Copyright and Permissions&#8221; tab_id=&#8221;1695203507185-d3c36cca-f855&#8243;][vc_column_text]This toolkit material is freely available for download by healthcare professionals and individual usage. For-profit organizations may link to toolkit materials with appropriate referencing but are not allowed to use the materials directly (including screenshots) in their own activities; and, where the toolkit materials are referenced with a link, society logos may not be used or displayed with the link. Non-profit organizations may link to the toolkit materials with appropriate referencing, and may promote the materials directly, but must seek permission for this first. If you have any questions concerning the rights to use these materials, please contact <a title=\"mailto:mmoorthy@theisn.org\" href=\"mailto:mmoorthy@theisn.org\">mmoorthy@theisn.org<\/a>.[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][vc_empty_space height=&#8221;40px&#8221;][vc_message message_box_color=&#8221;grey&#8221; icon_fontawesome=&#8221;fas fa-exclamation-triangle&#8221; el_class=&#8221;ref&#8221;]<em>This toolkit is intended to facilitate decision making of health professionals in their daily practice. However, final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate. All societies represented in this project\u00a0decline\u00a0any responsibilities for any damage caused by the use that may be\u00a0made of the information provided in this toolkit.<\/em>[\/vc_message][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_empty_space height=&#8221;14px&#8221;][vc_column_text] \u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0 \u00a0 [\/vc_column_text][vc_column_text]The toolkit on the\u00a0optimization of SGLT2i therapy is the next output of a multi-society cardio-kidney-metabolic initiative, led by the ISN, to co-create toolkits for advancing the prevention and management of cardio-kidney complications. The toolkit consists of\u00a0focused and practical infographics, serving as hands-on references for nephrologists, cardiologists and other [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":0,"parent":37555,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-45028","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/pages\/45028"}],"collection":[{"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/comments?post=45028"}],"version-history":[{"count":7,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/pages\/45028\/revisions"}],"predecessor-version":[{"id":54164,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/pages\/45028\/revisions\/54164"}],"up":[{"embeddable":true,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/pages\/37555"}],"wp:attachment":[{"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/media?parent=45028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}